Artelo Biosciences, Inc.

Artelo Biosciences, Inc. Announces Expanded Clinical Data to be Presented on both ART26.12 and ART27.13 at the 8th Annual Cannabinoid & Endocannabinoid Drug Development Summit https://lnkd.in/gbNUBJYG

We’re pleased to share that Artelo Biosciences, Inc. and our Phase 2 #CAReS results were recently featured in The Times (London) - including interviews with our CSO @DrAndyYates and Study Investigator Dr. Barry Laird. It’s encouraging to see our work gaining recognition as we continue advancing innovative science to improve patient outcomes. Read the full article here: https://lnkd.in/gMY2kbEx #Biotech #Innovation #CACS

In cancer anorexia-cachexia syndrome (#CACS), fatigue and loss of strength can rob patients of the ability to do the things that make life meaningful. In the Phase 2 #CAReS study, treatment with #ART27_13 was associated with improvements in physical activity, including both moderate and vigorous movement levels — measurable signs that patients were regaining energy and resilience. These functional gains are more than encouraging—they may represent clinically meaningful outcomes valued by regulators and, most importantly, by patients and their families. ART27.13 continues to demonstrate potential not only to help patients gain weight and muscle, but to restore vitality and daily function in those living with CACS. Learn more about the CAReS trial results: https://lnkd.in/g-NsmFA6

Weight is only part of the story. In cancer anorexia-cachexia syndrome (#CACS), patients often lose critical lean body mass—the muscle that supports strength, mobility, and daily activity. In the interim Phase 2 CAReS trial, patients treated with #ART27_13 gained an average of +4% lean body mass after one month, while those on placebo gained 0%. Preserving and rebuilding lean muscle means more than numbers on a scale—it represents hope for better function, independence, and quality of life for patients facing this devastating condition. Learn more about the trial results: https://lnkd.in/g-NsmFA6

Cancer anorexia-cachexia syndrome (#CACS) affects up to 80% of patients with advanced #cancer, causing significant weight loss, muscle wasting, and reduced quality of life. There are no FDA-approved treatments to address this critical condition. ART27.13 is showing promising results in a Phase 2 trial — helping patients gain weight, preserve lean body mass, and improve activity levels and has the potential to improve the lives of thousands of people who currently face limited options. #CancerCare #CachexiaAwareness #MedicalInnovation #CancerResearch #ART27_13

Artelo Biosciences, Inc. Announces Presentation of Positive Interim Phase 2 CAReS Data on ART27.13 at the 2025 Cancer Cachexia Society Conference https://lnkd.in/g7z2uAUs

Artelo Biosciences, Inc. Announces Publication of Preclinical Data Demonstrating Superior Efficacy and Bioavailability of ART12.11 in Reducing Stress-Induced #Depression and #Anxiety Symptoms https://lnkd.in/gK8NR-Kv

Artelo Biosciences, Inc. Announces Positive Interim Phase 2 CAReS Results for the Treatment of #Cancer #Anorexia-Cachexia Syndrome (#CACS) https://lnkd.in/gN284BPW

Artelo Biosciences, Inc. Announces New Data from an Initial Food Effect Investigation with ART26.12, a Novel Non-Opioid Treatment Candidate for Persistent #Pain https://lnkd.in/gYYYEcgH

Artelo Biosciences, Inc. Provides Business Update and Reports Second Quarter 2025 Financial Results https://lnkd.in/gAVNTZGz